A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: A EuroSIDA study

HIV Medicine

Volumn 12, Issue 5, 2011, Pages 259-268

  Reekie, J ^a   Reiss, P ^b   Ledergerber, B ^c   Sedlacek, D ^d   Parczewski, M ^e   Gatell, J ^f   Katlama, C ^g   Fatkenheuer G ^h   Lundgren, Jd ^i,j   Mocroft, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CHARLES UNIVERSITY   (Czech Republic)

^e POMERANIAN MEDICAL UNIVERSITY   (Poland)

^f HOSPITAL CLÍNIC   (Spain)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ Rigshospitalet   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Antiviral therapy; Durability; Long term adverse events

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DETERIORATION; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPLAN MEIER METHOD; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PANCREAS DISEASE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT FAILURE; VIRUS LOAD; WEIGHT REDUCTION;

ARGENTINA; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; ISRAEL; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79953283213     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00877.x     Document Type: Article

References (30)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, November 3 2008. 1-139. Available at (accessed 7 April 2009).
2. d'Arminio Monforte A, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499-507.
3. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-1327.
4. Mocroft A, Phillips AN, Soriano V et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21: 743-752.
5. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
6. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002; 34: 1137-1142.
7. Smith CJ, Mocroft A, Lundgren JD. Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. AIDS 2008; 22: 997-998.
8. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
9. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
10. Mocroft A, Horban A, Clumeck N et al. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naive patients starting cART after January 1, 2000. HIV Clin Trials 2006; 7: 271-284.
11. Crespo M, Ribera E, Suarez-Lozano I et al. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. J Antimicrob Chemother 2009; 63: 189-196.
12. Rodriguez-Arrondo F, Aguirrebengoa K, Portu J et al. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. Curr HIV Res 2009; 7: 526-532.
13. Nachega JB, Hislop M, Dowdy DW et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22: 2117-2125.
14. Santos J, Palacios R, Lozano F et al. Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up. AIDS Res Hum Retroviruses 2008; 24: 24-26.
15. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
16. Mocroft A, Staszewski S, Weber R et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+T-cell counts. Antivir Ther 2007; 12: 325-333.
17. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13: 943-950.
18. Zeuzem S, Alberti A, Rosenberg W et al. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther 2006; 24: 1133-1149.
19. Matthews GV, Sabin CA, Mandalia S et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16: 53-61.
20. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002; 185: 1062-1069.
21. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002; 3: 296-303.
22. Phillips AN, Pradier C, Lazzarin A et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15: 2385-2395.
23. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
24. Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr 2009; 51: 140-146.
25. Soriano V, Köppe S, Mingrone H et al. Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results. 5th International AIDS Society Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa, July 2009 [Abstract LBPEB07].
26. Bannister WP, Ruiz L, Cozzi-Lepri A et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008; 22: 367-376.
27. Lodwick RK, Smith CJ, Youle M et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22: 1039-1046.
28. van der Valk, Kastelein JJ, Murphy RL et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-2414.
29. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003; 4: 29-36.
30. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19.